254 related articles for article (PubMed ID: 20464345)
21. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
[TBL] [Abstract][Full Text] [Related]
22. Extending the skeletal muscle viability period in the malignant hyperthermia test.
Bina S; Holman S; Muldoon SM
Anesth Analg; 2003 Jan; 96(1):153-8, table of contents. PubMed ID: 12505942
[TBL] [Abstract][Full Text] [Related]
23. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].
Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD
Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497
[TBL] [Abstract][Full Text] [Related]
24. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
25. 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.
Wappler F; Scholz J; Fiege M; Richter A; Steinfath M; Weisshorn R; Schulte am Esch J
Naunyn Schmiedebergs Arch Pharmacol; 1999 Oct; 360(4):376-81. PubMed ID: 10551274
[TBL] [Abstract][Full Text] [Related]
26. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
Ginz HF; Girard T; Censier K; Urwyler A
Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
[TBL] [Abstract][Full Text] [Related]
27. Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans.
Melton AT; Antognini JF; Gronert GA
Acta Anaesthesiol Scand; 1999 Aug; 43(7):764-9. PubMed ID: 10456818
[TBL] [Abstract][Full Text] [Related]
28. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
[TBL] [Abstract][Full Text] [Related]
29. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia.
Kindler CH; Girard T; Gong D; Urwyler A
Anesth Analg; 2002 Apr; 94(4):1028-33, table of contents. PubMed ID: 11916818
[TBL] [Abstract][Full Text] [Related]
30. Analysis of histomorphology in malignant hyperthermia-susceptible patients.
Orlov D; Keith J; Rosen D; Croul S; Kraeva N; Riazi S
Can J Anaesth; 2013 Oct; 60(10):982-9. PubMed ID: 23888335
[TBL] [Abstract][Full Text] [Related]
31. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
32. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
33. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
[TBL] [Abstract][Full Text] [Related]
34. Malignant hyperthermia in humans--standardization of contracture testing protocol.
Melton AT; Martucci RW; Kien ND; Gronert GA
Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643
[TBL] [Abstract][Full Text] [Related]
35. Malignant Hyperthermia Susceptibility and Fitness for Duty.
Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
[TBL] [Abstract][Full Text] [Related]
36. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
Britt BA; Scott EA
Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
[TBL] [Abstract][Full Text] [Related]
37. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
38. [Tests of contracture and sensitivity to malignant hyperthermia in 27 patients].
Krivosic-Horber R; Adnet P; Krivosic I; Theunynck D; Guévart E; Adamantidis M
Ann Fr Anesth Reanim; 1988; 7(2):132-8. PubMed ID: 3364812
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
[TBL] [Abstract][Full Text] [Related]
40. [Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia].
Wang YL; Guo XY; Xu ZH; Huang YG; Luo AL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):182-6. PubMed ID: 18505122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
